Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perrigo CoPRGO +0.94%44 Equity-to-Asset is 0.31 as of Mar. 2026, which is 37% below its 10-year median of 0.49. GuruFocus rates PRGO with a GF Score™ of 44/100 and a GF Value™ of $24.89 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Perrigo Co ranks worse than 82.24% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Perrigo Co's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $2,499 Mil. Perrigo Co's Total Assets for the quarter that ended in Mar. 2026 was $7,983 Mil.
Therefore, Perrigo Co's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.31.
The historical rank and industry rank for Perrigo Co's Equity-to-Asset or its related term are showing as below:
PRGO'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31 Med: 0.49 Max: 0.53
Current: 0.31
During the past 13 years, the highest Equity to Asset Ratio of Perrigo Co was 0.53. The lowest was 0.31. And the median was 0.49.
PRGO's Equity-to-Asset is ranked worse than 82.24% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs PRGO: 0.31
Perrigo Co (NYSE:PRGO) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Perrigo Co Equity-to-Asset Related Terms
Perrigo Co Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Perrigo Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRGO vs PAHC, HROW, XERS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Perrigo Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Perrigo Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perrigo Co (PRGO) has a Equity-to-Asset of 0.31 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Perrigo Co and its competitors. This is 37% below median its historical median of 0.49. Over the past decade, Perrigo Co's Equity-to-Asset has ranged from 0.31 to 0.53. According to the industry distribution chart, Perrigo Co ranks #829 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 82.2%.
Is Perrigo Co's Equity-to-Asset too high?
Perrigo Co's current Equity-to-Asset of 0.31 is 37% below median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 0.53. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Perrigo Co's value of 0.31 is 49.2% below this industry median. Based on the distribution chart, Perrigo Co ranks #829 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Perrigo Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Perrigo Co's Equity-to-Asset compare to PAHC and HROW?
According to the Drug Manufacturers industry distribution chart, Perrigo Co ranks #829 out of 1008 companies for Equity-to-Asset. This places Perrigo Co in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Perrigo Co's value of 0.31 is 49.2% below this benchmark. Historically, Perrigo Co's own Equity-to-Asset has ranged from 0.31 to 0.53 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 0.61, Perrigo Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perrigo Co's current Equity-to-Asset of 0.31 is 49.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Perrigo Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perrigo Co's current Equity-to-Asset is 0.31, which is 37% below median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perrigo Co stock overvalued right now?
Based on GuruFocus' analysis, Perrigo Co (PRGO) is currently considered Possible Value Trap. The stock's GF Value™ is $24.89, compared to a current price of $10.78 — trading 56.7% below its estimated fair value. The current Equity-to-Asset is 0.31, which is 37% below median its 10-year median of 0.49 and 49.2% below the Drug Manufacturers industry median of 0.61. Perrigo Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Perrigo Co (PRGO), the current Equity-to-Asset is 0.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perrigo Co (PRGO) Overvalued in 2026?
Based on GuruFocus' analysis, Perrigo Co stock appears to be undervalued.
The current stock price of $10.78 is trading 56.7% below its estimated GF Value™ of $24.89.
GuruFocus considers Perrigo Co to be Possible Value Trap.
Key valuation signals for PRGO:
Equity-to-Asset: 0.31 (37% below median its 10-year median of 0.49)
GF Value™: $24.89 vs. price of $10.78 (56.7% below fair value)
Industry Position: 49.2% below the Drug Manufacturers median (#829 of 1008)
No single metric tells the full story. See the PRGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
44GF Score
Get the complete analysis for PRGO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRGO has been successfully added to your 
